Why the study?
Do NOACs reduce stroke, systemic embolism, and bleeding compared to VKAs in patients with atrial fibrillation and polypharmacy?
Do NOACs reduce stroke, systemic embolism, and bleeding compared to VKAs in patients with atrial fibrillation and polypharmacy?
In atrial fibrillation patients with polypharmacy, NOACs offer superior efficacy for stroke/systemic embolism prevention and lower risk of any bleeding compared to VKAs, with comparable rates of major bleeding and death.
Supports preferring NOACs over VKAs in AF with polypharmacy for lower stroke/systemic embolism and any bleeding; extends evidence to this subgroup.
In patients with AF and polypharmacy, NOACs showed advantages over VKAs in stroke or systemic embolism and any bleeding, and were comparable to VKAs for major bleeding, ischemic stroke, all-cause death, intracranial hemorrhage, and gastrointestinal bleeding.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: